Clinical practice guidelines for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions;Guías de práctica clínica para la evaluación y tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales

Endocrinologia y Nutricion

Volumn 59, Issue 3, 2012, Pages 174-196

  Reyes García, Rebeca ^a   Jódar Gimeno, Esteban ^b   García Martín, Antonia ^c   Romero Muñoz, Manuel ^a   Gómez Sáez, José Manuel ^d   Luque Fernández, Inés ^e   Varsavsky, Mariela ^f   Guadalix Iglesias, Sonsoles ^g   Cano Rodriguez, Isidoro ^h   Ballesteros Pomar, María Dolores ^h   Vidal Casariego, Alfonso ^h   Rozas Moreno, Pedro ⁱ   Cortés Berdonces, María ^j   Fernández García, Diego ^k   Calleja Canelas, Amparo ^l   Palma Moya, Mercedes ^j   Martínez Díaz Guerra, Guillermo ^g   Jimenez Moleón, José J ^m   Muñoz Torres, Manuel ^c  

^a HOSPITAL RAFAEL MÉNDEZ   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL VIRGEN DE LA SALUD   (Spain)

^f Hospital de Sant Pau i Santa Tecla   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h Complejo Asistencial Universitario de León   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^j Hospital Gutiérrez Ortega de Valdepeñas   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^l UNIVERSITY CLINIC OF NAVARRA   (Spain)

^m UNIVERSITY OF GRANADA   (Spain)

more..

Author keywords

Diagnosis; Endocrine diseases; Fractures; Nutritional diseases; Osteoporosis; Treatment

Indexed keywords

ARTICLE; BONE DENSITY; BONE MASS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE ASSOCIATION; ENDOCRINE DISEASE; FRACTURE; FRAGILITY FRACTURE; HUMAN; MEDICAL SOCIETY; MEDLINE; NUTRITIONAL DISORDER; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RISK FACTOR; SYSTEMATIC REVIEW;

ABSORPTIOMETRY, PHOTON; ALGORITHMS; ANOREXIA NERVOSA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIABETES COMPLICATIONS; DISEASE MANAGEMENT; ENDOCRINE SYSTEM DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MALNUTRITION; OSTEOPOROSIS; PARENTERAL NUTRITION; POSTGASTRECTOMY SYNDROMES; VITAMIN D;

EID: 84858293764     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2012.01.002     Document Type: Article

References (282)

1. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., et al. Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490.
2. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int 2007, 18:427-444.
3. Hamilton E.J., Rakic V., Davis W.A., Chubb S.A., Kamber N., Prince R.L., et al. Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes. Diabet Med 2009, 26:45-52.
4. Massé P.G., Pacifique M.B., Tranchant C.C., Arjmandi B.H., Ericson K.L., Donovan S.M., et al. Bone metabolic abnormalities associated with well-controlled type 1 diabetes (IDDM) in youngadult women: a disease complication often ignored or neglected. J Am Coll Nutr 2010, 29:419-429.
5. Soto N., Pruzzo R., Eyzaguirre F., Iñiguez G., López P., Mohr J., et al. Bone mass and sex steroids in postmenarcheal adolescents and adult women with Type 1 diabetes mellitus. J Diabetes Complications 2011, 25:19-24.
6. Lopez-Ibarra P.J., Pastor M.M., Escobar-Jimenez F., Pardo M.D., Gonzalez A.G., Luna J.D., et al. Bone mineral density at time of clinical diagnosis of adult- onset type 1 diabetes mellitus. Endocr Pract 2001, 7:346-351.
7. Campos Pastor M.M., Lopez-Ibarra P.J., Escobar-Jimenez F., Serrano Pardo M.D., Garcia-Cervigon A.G. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: A prospective study. Osteoporos Int 2000, 11:455-459.
8. Muñoz-Torres M., Jodar E., Escobar-Jimenez F., Lopez-Ibarra P.J., Luna J.D. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin- dependent diabetes mellitus. Calcif Tissue Int 1996, 58:316-319.
9. Clausen P., Feldt-Rasmussen B., Jacobsen P., Rossing K., Parving H.H., Nielsen P.K., et al. Microalbuminuria as an early indicator of osteopenia in male insulin-dependent diabetic patients. Diabet Med 1997, 14:1038-1043.
10. Rix M., Andreassen H., Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 1999, 22:827-831.
11. Hampson G., Evans C., Petitt R.J., Evans W.D., Woodhead S.J., Peters J.R., et al. Bone mineral density, collagen type 1 alpha 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 1998, 41:1314-1320.
12. Ingberg C.M., Palmer M., Aman J., Arvidsson B., Schvarcz E., Berne C. Body composition and bone mineral density in long-standing type 1 diabetes. J Intern Med 2004, 255:392-398.
13. Bridges M.J., Moochhala S.H., Barbour J., Kelly C.A. Influence of diabetes on peripheral bone mineral density in men: A controlled study. Acta Diabetol 2005, 42:82-86.
14. Janghorbani M., Van Dam R.M., Willett W.C., Hu F.B. Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture. Am J Epidemiol 2007, 166:495-505.
15. Miao J., Brismar K., Nyren O., Ugarph-Morawski A., Ye W. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study inSweden. Diabetes Care 2005, 28:2850-2855.
16. Ahmed L.A., Joakimsen R.M., Berntsen G.K., Fønnebø V., Schirmer H. Diabetes mellitus and the risk of non-vertebral fractures: The Tromsø Study. Osteoporos Int 2006, 17:495-500.
17. Neumann T., Sämann A., Lodes S., Kästner B., Franke S., Kiehntopf M., et al. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. Diabet Med 2011, 28:872-875.
18. Hanley D.A., Brown J.P., Tenenhouse A., Olszynski W.P., Ioannidis G., Berger C., et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 2003, 18:784-790.
19. Vestergaard P., Rejnmark L., Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005, 48:1292-1299.
20. Vestergaard P., Rejnmark L., Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes?. Calcif Tissue Int 2011, 88:209-214.
21. Anaforoglu I., Nar-Demirer A., Bascil-Tutuncu N., Ertorer M.E. Prevalence of osteoporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes. J Diabetes Complications 2009, 23:12-17.
22. Sosa M., Saavedra P., Jódar E., Lozano-Tonkin C., Quesada J.M., Torrijos A., et al. Bone mineral density and risk of fractures in aging, obese post-menopausal women with type 2 diabetes. The GIUMO Study. Aging Clin Exp Res 2009, 21:27-32. GIUMO Study Group.
23. Gupta R., Mohammed A.M., Mojiminiyi O.A., Alenizi E.K., Abdulla N.A. Bone mineral density in premenopausal Arab women with type 2 diabetes mellitus. J Clin Densitom 2009, 12:54-57.
24. Zhou Y., Li Y., Zhang D., Wang J., Yang H. Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes. Diabetes Res Clin Pract 2010, 90:261-269.
25. Sauque-Reyna L., Salcedo-Parra M.A., Sánchez-Vargas P.R., Flores-Helguera J.D., Badillo-Sánchez C., Reza-Albarrán A., et al. Bone mineral density in patients with type 2 diabetes. Rev Invest Clin 2011, 63:162-169.
26. Shan P.F., Wu X.P., Zhang H., Cao X.Z., Yuan L.Q., Liao E.Y. Age-related bone mineral density, osteoporosis rate and risk of vertebral fracture in mainland Chinese women with type 2 diabetes mellitus. J Endocrinol Invest 2011, 34:190-196.
27. Loke Y.K., Singh S., Furberg C.D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32-39.
28. Yamamoto M., Yamaguchi T., Yamauchi M., Kaji H., Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 2009, 24:702-709.
29. Ivers R.Q., Cumming R.G., Mitchell P., Peduto A.J. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 2001, 24:1198-1203.
30. Schwartz A.V., Sellmeyer D.E., Ensrud K.E., Cauley J.A., Tabor H.K., Schreiner P.J., et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001, 86:32-38.
31. Strotmeyer E.S., Cauley J.A., Schwartz A.V., Nevitt M.C., Resnick H.E., Bauer D.C., et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glu- cose in older white and black adults: The Health Aging, and Body Composition Study. Arch Intern Med 2005, 165:1612-1617.
32. De Liefde I.I., Van der Klift M., De Laet C.E., Van Daele P.L., Hofman A., Pols H.A. Bone mineral density and fracture risk in type-2 diabetes mellitus: The Rotterdam Study. Osteoporos Int 2005, 16:1713-1720.
33. Kanazawa I., Yamaguchi T., Yamamoto M., Sugimoto T. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab 2010, 28:554-560.
34. Kim JH, Jung MH, Lee JM, Son HS, Cha BY, Chang SA. Diabetic peripheral neuropathy is highly associated with non-traumatic fractures in Korean patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2011 Epub Sep 12.
35. Schwartz A.V., Vittinghoff E., Bauer D.C., Hillier T.A., Strotmeyer E.S., Ensrud K.E., et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011, 305:2184-2192. Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group.
36. Mancini T., Mazziotti G., Doga M., Carpinteri R., Simetovic N., Vescovi P.P., et al. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 2009, 45:784-788.
37. Habib Z.A., Havstad S.L., Wells K., Divine G., Pladevall M., Williams L.K. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95:592-600.
38. Kahn S.E., Zinman B., Lachin J.M., Haffner S.M., Herman W.H., Holman R.R., et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845-851.
39. Keegan T.H., Schwartz A.V., Bauer D.C., Sellmeyer D.E., Kelsey J.L. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004, 27:1547-1553.
40. Dagdelen S., Sener D., Bayraktar M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv Ther 2007, 24:1314-1320.
41. Silverberg S.J., Lewiecki E.M., Mosekilde L., Peacock M., Rubin M.R. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009, 94:351-365.
42. Rubin M.R., Bilezikian J.P., McMahon D.J., Jacobs T., Shane E., Siris E., et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008, 93:3462-3470.
43. Silverberg S.J., Shane E., Jacobs T.P., Siris E., Bilezikian J.P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341:1249-1255.
44. Khosla S., Melton L.J., Wermers R.A., Crowson C.S., O'Fallon W., Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999, 14:1700-1707.
45. Vestergaard P., Mollerup C.L., Frøkjaer V.G., Christiansen P., Blichert-Toft M., Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000, 321:598-602.
46. Bilezikian J.P., Khan A.A., Potts J.T. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab 2009, 94:335-339.
47. Vestergaard P., Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003, 327:530-534.
48. Ambrogini E., Cetani F., Cianferotti L., Vignali E., Banti C., Viccica G., et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007, 92:3114-3121.
49. Siilin H., Lundgren E., Mallmin H., Mellström D., Ohlsson C., Karlsson M., et al. Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World J Surg 2011, 35:1266-1272.
50. Khosla S., Melton J. Fracture risk in primary hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl 2):N103-N107.
51. Khan A.A., Bilezikian J.P., Potts J.T. Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab 2009, 94:333-334.
52. Eastell R., Arnold A., Brandi M.L., Brown E.M., D'Amour P., Hanley D.A., et al. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009, 94:340-350.
53. Udelsman R., Pasieka J.L., Sturgeon C., Young J.E., Clark O.H. Surgery for asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009, 94:366-372.
54. Khan A., Grey A., Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009, 94:373-381.
55. Khan A.A., Bilezikian J.P., Kung A.W., Ahmed M.M., Dubois S.J., Ho A.Y., et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89:3319-3325.
56. Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90:135-141.
57. Vestergaard P., Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk a meta-analysis. Thyroid 2003, 13:585-593.
58. Vestergaard P., Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 2002, 12:411-419.
59. Ben-Shlomo A., Hagag P., Evans S., Wiss M. Early postmenopausal bone loss in hyperthyroidism. Maturitas 2001, 39:19-27.
60. Jodar E., Muñoz-Torres M., Escobar-Jimenez F., Quesada-Charneco M., Luna del Castillo J.D. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clin Endocrinol (Oxf) 1997, 47:279-285.
61. Boonya-Ussadorn T., Punkaew B., Sriassawaamorn N. A comparative study of bone mineral density between premenopausal women with hyperthyroidism and healthy premenopausal women. J Med Assoc Thai 2010, 93(Suppl 6):S1-S5.
62. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995, 332:767-773.
63. Vestergaard P., Rejnmark L., Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 2005, 77:139-144.
64. Bauer D.C., Ettinger B., Nevitt M.C., Stone K.L. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001, 134:561-568.
65. Garnero P., Vassy V., Bertholi A., Riou J.P., Delmas P.D. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994, 78:955-959.
66. Mosekilde L., Eriksen E.F., Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990, 19:35-63.
67. Karga H., Papapetrou P.D., Korakovouni A., Papandroulaki F., Polymeris A., Pampaouras G. Bone mineral density in hyperthyroidism. Clin Endocrinol 2004, 61:466-472.
68. Udayakumar N., Chandrasekaran M., Raheed M.H., Suresh R.V., Sivaprakash S. Evaluation of bone mineral density in thyrotoxicosis. Singapore Med J 2006, 47:947-950.
69. Obermayer-Pietsch B., Dobning H., Warnkrob H., Dimai H.P., Weber K., Berghold A., et al. Variable bone mass recovery in hyperthyroid bone disease after radioiodine therapy in postmenopausal patients. Maturitas 2000, 35:159-166.
70. Jodar E., Muñoz-Torres M., Escobar-Jimenez F., Quesada M., Luna J.D., Olea N. Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. J Clin Endocrinol Metab 1997, 82:1989-1994.
71. Diamond T., Vine J., Smart R., Butler P. Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 1994, 120:8-11.
72. Kisakol G., Kaya A., Gonen S., Tunc R. Bone and calcium metabolism in subclinical autoinmune hyperthyroidism and hypothyroidism. Endocr J 2003, 50:657-661.
73. Földes J., Tarján G., Szathmari M., Varga F., Krasznai I., Horvath C. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?. Clin Endocrinol (Oxf) 1993, 39:521-527.
74. Belaya Z.E., Melnichenko G.A., Rozhinskaya L.Y., Fadeev V.V., Alekseeva T.M., Dorofeeva O.K., et al. Subclinical hyperthyroidism of variable etiology and its influence on bone in postmenopausal women. Hormones Athens 2007, 6:62-70.
75. Lee J., Buzkova P., Fink H., Vu J., Carbone L., Chen Z., et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 2010, 170:1876-1883.
76. Tauchmanovà L., Nuzzo V., Del Puente A., Fonderico F., Esposito-Del Puente A., Padulla S., et al. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas 2004, 48:299-306.
77. Vadiveloo T., Donnan P.T., Cochrane L., Leese G.P. The thyroid epidemiology, autid, and research study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011, 96:1344-1351.
78. Bauer D., Nevitt M., Ettinger D., Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 1997, 82:2931-2936.
79. Faber J., Overgaard K., JarIov A., Christiansen C. Bone metabolism in premenopausal women with nontoxic goiter and reduced serum thyrotropin levels. Thyroidology 1994, 6:27-36.
80. Ugur-Altun D., Altun A., Arikan E., Guldiken S., Tugrul A. Relationships existing between the serum cytokine levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism. Endocr Res 2003, 290:389-398.
81. Faber J., Jensen I.W., Petersen L., Nygaard B., Hegedus L., Siersbaek-Nielsen K. Normalization of serum thyrotropin by mean of radioiodine treatment in subclinical hyperthyroidism. Effect of bone loss in postmenopausal women. Clin Endocrinol 1998, 48:285-290.
82. Muddle A.H., Houben A.J., Nieuwenhuijzen Kruseman A.C. Bone metabolism during anti thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol 1994, 41:421-424.
83. Ahmed L.A., Schirmer H., Berntsen G.K., Fønnebø V., Joakimsen R.M. Self-reported diseases and the risk of non-vertebral fractures: the Tromsø study. Osteoporos Int 2006, 17:46-53.
84. Hanna F., Pettit R., Ammari F., Evans W.D., Sandeman D., Lazarus J.H. Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol (oxf) 1998, 48:229-234.
85. Salerno M., Lettiero T., Esposito-del Puente A., Esposito V., Capalbo D., Carpinelli A. Effect of long-term L-thyroxine treatment on bone mineral density in young adults with congenital hypothyroidism. Eur J Endocrinol 2004, 151:689-694.
86. Uzzan B., Campos J., Cucherat M., Nony P., Boissel J.P., Perret G.Y. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996, 81:4278-4289.
87. Turner M., Camacho X., Fischer H.D., Austin P.C., Anderson G.M., Rochon P., et al. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ 2011, 342:2238-2247.
88. Nagata M., Suzuki A., Sekiguchi S., Ono Y., Nishiwaki-Yasuda K., Itoi T., et al. Subclinical hypothyroidism is related to lower Heel QUS in postmenopausal women. Endocrine Journal 2007, 54:625-630.
89. Lee W.Y., Oh K.W., Rhee E.J., ung C.H., Kim S.W., Yun E.J., et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. J Arch Med Res 2006, 37:511-516.
90. Meier C., Beat M., Guglielmetti M., Chris-Crain M., Staub J.J., Kraenzlin M. Restoration of euthyroidism accelerates bone turnover in patients eith subclinical hypothyroidism: a randomized controlled trial. Osteoporos int 2004, 15:209-216.
91. Faber J., Galloe A.M. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. European Journal of Endocrinology 1994, 130:350-356.
92. Affinito P., Sorrentino C., Jussie M., Di Carlo C., Moccia G., Canciello P., et al. Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism. Acta Obstet Gynecol Scand 1996, 75:843-848.
93. Chen C.H., Chen J.F., Yang B.Y., Liu R.T., Tung S.C., Chien W.Y., et al. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. J Formos Med Assoc 2004, 103:442-447.
94. Jodar E., Begona Lopez M., Garcia L., Rigopoulou D., Martínez G., Hawkins F. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos Int 1998, 8:311-316.
95. De Rosa G., Testa A., Giacomini D., Carrozza C., Astazi P., Caradonna P. Prospective study of bone loss in pre- and postmenopausal women on L-thyroxine therapy for non-toxic goiter. Clin Endocrinol (Oxf) 1997, 47:429-435.
96. Karner I., Hrgovic Z., Sijanovic S., Buković D., Klobucar A., Usadel K.H., et al. Bone mineral density changes and bone turnover in thyroid carcinoma patienets treated with supraphysiologic doses of thyroxine. Eur J Med Res 2005, 10:480-488.
97. Mazokopakis E.E., Starakis I.K., Papakomanolaki M.G., Batistakis A.G., Papadakis J.A. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy. Curr Med Res Opin 2006, 22:1369-1373.
98. Hejickmann C., Huijberts M., Geusens P., De Vries J., Menheere P., Wolffenbutel B. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. European Journal of Endocrinology 2005, 153:23-29.
99. Nuzzo V., Lupoli G., Del Puente A., Rampone E., Carpinelli A., Esposito Del Puente A., et al. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy. Gynecol Endocrinol 1998, 12:333-337.
100. Appetechia M. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study. Horm Res 2005, 64:293-298.
101. Baldini M., Gallazzi M., Orsatti A., Fossati S., Leonardi P., Cantalamessa L. Treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. J Intern Med 2002, 251:407-414.
102. Bauer M., Fairbanks L., Baghofer A., Hierholzer J., Bschor T., Baethge C., et al. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders. A longitudinal study. J Affect Disord 2004, 83:183-190.
103. Guo C., Weetman A., Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (oxf) 1997, 46:301-307.
104. Larijani B., Gharibdoost F., Pajouhi M., Sadjadi A., Aghakhani S., Eshraghian R., et al. Effects of levothyroxina suppressive therapy on bone mineral density in premenopausal women. J Clin Pharm Ther 2004, 29:1-5.
105. Marcocci C., Golia F., Vignali E., Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Metab 1997, 12:72-77.
106. Rosen H., Moses A., Garber J., Ross D.S., Lee S.L., Ferguson L., et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998, 83:2324-2330.
107. Sajjinanont T., Rajchadara S., Sriassawaamorn N., Panichkul S. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women. J Med Assoc Thai 2005, 88(suppl 3):S71-S76.
108. Flynn R., Bonellie S., Jung R., MacDonald T., Morris A., Leese G. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patiens on long-term thyroxine therapy. J Clin Endocrinol Metab 2010, 95:186-193.
109. Mircea C.N., Lujan M.E., Pierson R.A. Metabolic fuel and clinical implications for female reproduction. J Obstet Gynaecol Can 2007, 29:887-902.
110. Gordon C.M. Bone density issues in the adolescent gynecology patient. J Pediatr Adolesc Gynecol 2000, 13:157-161.
111. Conway G.S., Band M., Doyle J., Davies M.C. How do you monitor the patient with Turner's syndrome in adulthood?. Clin Endocrinol (Oxf) 2010, 73:696-699.
112. Meczekalski B., Podfigurna-Stopa A., Genazzani A.R. Hypoestrogenism in young women and its influence on bone mass density. Gynecol Endocrinol 2010, 26:652-657.
113. Hadji P., Body J.J., Aapro M.S., Brufsky A., Coleman R.E., Guise T., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416.
114. Rabaglio M., Sun Z., Price K.N., Castiglione-Gertsch M., Hawle H., Thürlimann B., et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009, 20:1489-1498.
115. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141.
116. Brufsky A.M., Bosserman L.D., Caradonna R.R., Haley B.B., Jones C.M., Moore H.C., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
117. Hines S.L., Mincey B., Dentchev T., Sloan J.A., Perez E.A., Johnson D.B., et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 2009, 117:603-609.
118. Greenspan S.L., Brufsky A., Lembersky B.C., Bhattacharya R., Vujevich K.T., Perera S., et al. Risedronate prevents bone loss inbreast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008, 26:2644-2652.
119. Van Poznak C., Hannon R.A., Mackey J.R., Campone M., Apffelstaedt J.P., Clack G., et al. Prevention of aromatase inhibitorinduced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28:967-975.
120. Lester J.E., Dodwell D., Purohit O.P., Gutcher S.A., Ellis S.P., Thorpe R., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
121. Ellis G.K., Bone H.G., Chlebowski R., Paul D., Spadafora S., Smith J., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875-4882.
122. Seo J.T., Lee J.S., Oh T.H., Joo K.J. The clinical significance of bone mineral density and testosterone levels in Korean men with non-mosaic Klinefelter's syndrome. BJU Int 2007, 99:141-146.
123. Breuil V., Euller-Ziegler L. Gonadal dysgenesis and bone metabolism. Joint Bone Spine 2001, 68:26-33.
124. Van den Bergh J.P., Hermus A.R., Spruyt A.I., Sweep C.G., Corstens F.H., Smals A.G. Bone mineral density and quantitative ultrasound parameters in patients with Klinefelter's syndrome after long-term testosterone substitution. Osteoporos Int 2001, 12:55-62.
125. Bassil N. Late-onset hypogonadism. Med Clin North Am 2011, 95:507-523.
126. Shimon I., Eshed V., Doolman R., Sela B.A., Karasik A., Vered I. Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int 2005, 16:1591-1596.
127. Ringe J.D., Faber H., Farahmand P., Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006, 26:427-431.
128. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
129. Maillefert J.F., Sibilia F., Saussine C., Javier R.M., Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonist for prostatic carcinoma. J Urol 1999, 161:1219-1222.
130. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of Fracture after Androgen Deprivation for Prostate Cancer. N Engl J Med 2005, 352:154-164.
131. Michaelson M.D., Kaufman D.S., Lee H., McGovern F.J., Kantoff P.W., Fallon M.A., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.
132. Ryan C.W., Huo D., Bylow K., Demers L.M., Stadler W.M., Henderson T.O., et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007, 100:70-75.
133. Israeli R.S., Rosenberg S.J., Saltzstein D.R., Gottesman J.E., GoldsteinHR, Hull G.W., et al. The effect of zolendronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007, 5:271-277.
134. Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002, 1:145-152.
135. Greenspan S.L., Nelson J.B., Trump D.L., Resnick N.M. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416-424.
136. Smith M.R., Egerdie B., Hernández Toriz N., Feldman R., Tammela T.L., Saad F., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755. Denosumab HALT Prostate Cancer Study Group.
137. Fizazi K., Bosserman L., Gao G., Skacel T., Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009, 182:509-515.
138. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19:1395-1408. National Osteoporosis Guideline Group.
139. Colao A., Di Somma C., Pivonello R., Loche S., Aimaretti G., Cerbone G., et al. Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism. J Clin Endocrinol Metab 1999, 84:1919-1924.
140. Murray R.D., Columb B., Adams J.E., Shalet S.M. Low Bone Mass Is an Infrequent Feature of the Adult Growth Hormone Deficiency Syndrome in Middle-Age Adults and the Elderly. J Clin Endocrinol Metab 2004, 89:1124-1130.
141. Rosén T., Hannson T., Granhed H., Szucs J., Bengtsson B.A. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinologica 1993, 129:201-206.
142. Toogood A., Adams J.E., O'Neill P.A., Shalet S.M. Elderly Patients with Adult-Onset Growth Hormone Deficiency Are Not Osteopenic. J Clin Endocrinol Metab 1997, 82:1462-1466.
143. Rosén T., Wilhelmsen L., Landin-Wilhelmsen K., Lappas G., Bengtsson B.A. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997, 137:240-245.
144. Vestergaard, Jorgensen J.O., Hagen C., Hoeck H.C., Laurberg P., Rejnmark L., et al. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas - a case-control study. Clin Endocrinol (Oxf) 2002, 56:159-166.
145. Wüster C., Abs R., Bengtsson B.-A., Bennmarker H., Feldt-Rasmussen U., Hernberg-Stahl E., et al. The Influence of Growth Hormone Deficiency. Growth Hormone Replacement Therapy, and Other Aspects of Hypopituitarism on Fracture Rate and Bone Mineral Density. J Bone Miner Res 2001, 16:398-404. on Behalf of the KIMS Study Group and the KIMS International Board.
146. Mazziotti G., Bianchi A., Bonadonna S., Nuzzo M., Cimino V., Fusco A., et al. Increased Prevalence of Radiological Spinal Deformities in Adult Patients With GH Deficiency: Influence of GH Replacement Therapy. J Bone Miner Res 2006, 21:520-528.
147. Holmes S.J., Whitehouse R.W., Swindell R., Economou G., Adams J.E., Shalet S.M. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol (Oxf) 1995, 42:627-633.
148. Cuneo R.S., Judd S., Wallace J.D., Perry-Keene D., Burger H., Lim-Tio S., et al. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Metab 1998, 83:107-116.
149. Kann P., Piepkorn B., Schehler B., Andreas J., Lotz J., Prellwitz W., et al. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf) 1998, 48:561-568.
150. Rahim A., Holmes S.J., Adams J.E., Shalet S.M. Long-term changes in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy. Clin Endocrinol (Oxf) 1998, 48:463-469.
151. Hansen T.B., Brixen K., Vahl N., Jørgensen J.O., Christiansen J.S., Mosekilde L., et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 1996, 81:3352-3359.
152. Götherström G., Bengtsson B.-A., Bosaeus I., Johannsson G., Svensson J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol 2007, 156:55-64.
153. Biermasz N.R., Hamdy N.A., Janssen Y.J., Roelfsema F. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J Clin Endocrinol Metab 2001, 86:3079-3085.
154. Biermasz N.R., Hamdy N., Pereira A.M., Romijn J.A., Roelfsema F. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocinol (Oxf) 2004, 60:568-575.
155. White H.D., Ahmad A.M., Durham B.H., Joshi A.A., Fraser W.D., Vora J.P. Effect of Oral Phosphate and Alendronate on Bone Mineral Density when given as adjunctive therapy to growth hormone replacement in Adult Growth hormone deficiency. J Clin Endocrinol Metab 2011, 93:726-736.
156. Shalet S.M., Shavrikova, Cromer M., Child C.J., Eberhard K., Zapletalova J., et al. Effect of Growth Hormone (GH) Treatment on Bone in Postpubertal GH-Deficient Patients: A 2-Year Randomized, Controlled Dose-Ranging Study. J Clin Endocrinol Metab 2003, 88:4124-4129.
157. Drake W.M., Carroll P.V., Maher K.T., Metcalfe K.A., Camacho-Hübner C., Shaw N.J., et al. The Effect of Cessation of Growth Hormone (GH) Therapy on Bone Mineral Accretion in GH-Deficient Adolescents at the Completion of Linear Growth. J Clin Endocrinol Metab 2003, 88:1658-1663.
158. Underwood L.E., Attie K.M., Baptista J. Growth Hormone (GH) Dose-Response in Young Adults with Childhood-Onset GH Deficiency: A Two-Year, Multicenter, Multiple-Dose Placebo-Controlled Study. J Clin Endocrinol Metab 2003, 88:5273-5280. The Genentech Collaborative Study Group.
159. Vestergaard P., Lindholm J., Jørgensen J.O., Hagen C., Hoeck H.C., Laurberg P., et al. Increased risk of osteoporotic fractures in patients with Cushing's syndrome. Eur J Endocrinol 2002, 146:51-56.
160. Ohmori N., Nomura K., Ohmori K., Kato Y., Itoh T., Takano K. Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome. Endocr J 2003, 50:1-7.
161. Tauchmanovà L., Pivonello R., Di Somma C., Rossi R., De Martino M.C., Camera L., et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 2006, 91:1779-1784.
162. Tauchmanovà L., Pivonello R., De Martino M.C., Rusciano A., De Leo M., Ruosi C., et al. Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. Eur J Endocrinol 2007, 157:359-366.
163. Kristo C., Jemtland R., Ueland T., Godang K., Bollerslev J. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 2006, 154:109-118.
164. Füto L., Toke J., Patócs A., Szappanos A., Varga I., Gláz E., et al. Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome. Osteoporos Int 2008, 19:941-949.
165. Di Somma C., Colao A., Pivonello R., Klain M., Faggiano A., Tripodi F.S., et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf) 1998, 48:655-662.
166. Torlontano M., Chiodini I., Pileri M., Guglielmi G., Cammisa M., Modoni S., et al. Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism. J Clin Endocrinol Metab 1999, 84:2381-2385.
167. Rossi R., Tauchmanova L., Luciano A., Di Martino M., Battista C., Del Viscovo L., et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000, 85:1440-1448.
168. Osella G., Reimondo G., Peretti P., Alì A., Paccotti P., Angeli A., et al. The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis. J Clin Endocrinol Metab 2001, 86:604-607.
169. Hadjidakis D., Tsagarakis S., Roboti C., Sfakianakis M., Iconomidou V., Raptis S.A., et al. Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas?. Clin Endocrinol (Oxf) 2003, 58:72-77.
170. Chiodini I., Morelli V., Masserini B., Salcuni A.S., Eller-Vainicher C., Viti R., et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab 2009, 94:3207-3214.
171. Chiodini I., Guglielmi G., Battista C., Carnevale V., Torlontano M., Cammisa M., et al. Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab 2004, 89:2237-2241.
172. Chiodini I., Torlontano M., Carnevale V., Guglielmi G., Cammisa M., Trischitta V., et al. Bone loss rate in adrenal incidentalomas: a longitudinal study. J Clin Endocrinol Metab 2001, 86:5337-5341.
173. Morelli V., Eller-Vainicher C., Salcuni A.S., Coletti F., Iorio L., Muscogiuri G., et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 2011, 26:1816-1821.
174. Tauchmanova L., Guerra E., Pivonello R., De Martino M.C., De Leo M., Caggiano F., et al. Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome. J Endocrinol Invest 2009, 32:390-394.
175. Braatvedt G.D., Joyce M., Evans M., Clearwater J., Reid I.R. Bone mineral density in patients with treated Addison's disease. Osteoporos Int 1999, 10:435-440.
176. Koetz K.R., Ventz M., Diederich S., Quinkler M. Bone Mineral Density Is Not Significantly Reduced in Adult Patients on Low-Dose Glucocorticoid Replacement Therapy. J Clin Endocrinol Metab 2011 Oct 12, 10.1210/jc2011-jc2036.
177. Devegelaer J.P., Crabbé J., Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. BMJ 1987, 294:798-800.
178. Valero M.A., León M., Ruiz Valdepeñas M.P., Larrodera L., López M.B., Papapietro K., et al. Bone density and turnover in Addison's disease: effect of glucocorticoid treatment. Bone Miner 1994, 26:9-17.
179. Jodar E., Ruiz Valdepeñas M.P., Martínez G., Jara A., Hawkins F. Long-term follow-up of bone mineral density in Addison's disease. Clin Endocrinol 2003, 58:617-620.
180. Zelissen P.M.J., Croughs R.J., Van Rijk P.P., Raymakers J.A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994, 120:207-210.
181. Leelarathna L., Breen L., Powrie J.K., Thomas S.M., Guzder R., McGowan B., et al. Co-morbidities, management and clinical outcome of auto-inmune Addison's disease. Endocrine 2010, 38:113-117.
182. Lovas K., Gjesdal C.G., Christensen M., Wolf A.B., Almas B., Svartberg J., et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009, 160:993-1002.
183. Gurnell E.M., Hunt P.J., Curran S.E., Conway C.L., Pullenayegum E., Huppert F.A., et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab 2008, 93:400-409.
184. Coates P.S., Fernstrom J.D., Fernstrom M.H., Schauer P.R., Greenspan S.L. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and decrease in bone mass. J Clin Endocrinol Metab 2004, 89:1061-1065.
185. Nogués X., Goday A., Peña M.J., Benaiges D., De Ramón M., Crous X., et al. Bone mass loss after sleeve gastrectomy: a prospective comparative study with gastric bypass. Cir Esp 2010, 88:103-109.
186. Dixon J.B., Strauss B.J., Laurie C., O'Brien P.E. Changes in body composition with weight loss: obese subjects randomized to surgical and medical programs. Obesity (Silver Spring) 2007, 15:1187-1198.
187. Pereira F.A., De Castro J.A., Dos Santos J.E., Foss M.C., Paula F.J. Impact of marked weight loss induced by bariatric surgery on bone mineral density and remodeling. Braz J Med Biol Res 2007, 40:509-517.
188. Goode L.R., Brolin R.E., Chowdhury H.A., Shapses S.A. Bone and gastric bypass surgery: effects of dietary calcium and vitamin D. Obes Res 2004, 12:40-47.
189. Vilarrasa N., Gómez J.M., Elio I., Gómez-Vaquero C., Masdevall C., Pujol J., et al. Evaluation of bone disease in morbidly obese women after gastric bypass and risk factors implicated in bone loss. Obes Surg 2009, 19:860-866.
190. Soleymani T., Tejavanija S., Morgan S. Obesity, bariatric surgery, and bone. Curr Opin Rheumatol 2011, 23:396-405.
191. Mechanick J.I., Kushner R.F., Sugerman H.J., Gonzalez-Campoy J.M., Collazo-Clavell M.L., Guven S., et al. The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract 2008, 14(Suppl 1):1-83. American Association of Clinical Endocrinologists.
192. Mechanick J.I. Bariatric surgery and the role of the clinical endocrinologist: 2011 update. Endocr Pract 2011, 17:788-797.
193. Heber D., Greenway F.L., Kaplan L.M., Livingston E., Salvador J., Still C. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95:4823-4843.
194. Tondapu P., Provost D., Adams-Huet B., Sims T., Chang C., Sakhaee K. Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. Obes Surg 2009, 19:1256-1261.
195. Williams S.E. Metabolic bone disease in the bariatric surgery patient. J Obes 2011, 2011:634614.
196. Carlin A.M., Rao D.S., Yager K.M., Parikh N.J., Kapke A. Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial. Surg Obes Relat Dis 2009, 5:444-449.
197. National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28-30, 2004. Gastroenterology 2005;128:1-9.
198. Jones R.B., Robins G.G., Howdle P. Advances in celiac disease. Curr Opin Gastroenterol 2006, 22:117-123.
199. Bianchi B.L., Bardella M.T. Bone in celiac disease. Osteoporos Int 2008, 19:1705-1716.
200. Tilg H., Moschen A.R., Kaser A., Pines A., Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008, 57:684-694.
201. Corazza G.R., Di Stefano M., Mauriño E., Bai J.C. Bones in coeliac disease: diagnosis and treatment. Best Pract Res Clin Gastroenterol 2005, 19:453-465.
202. Lewis N.R., Scott B.B. Should patients with coeliac disease have their bone mineral density measured?. Eur J Gastroenterol & Hepatol 2005, 17:1065-1070.
203. Lewis NR and Scott BB. Guidelines for osteoporosis in inflammatory bowel disease and celiac disease. British Society of Gastroenterology. [consultado Jun 2007].Disponible en: http://www.bsg.org.uk/.
204. Meyer D., Stavropolous S., Diamond B., Shane E., Green P. Osteoporosis in a North American adult population with celiac disease. Am J Gastroenterol 2001, 96:112-119.
205. Duerksen D.R., Leslie W.D. Positive celiac disease serology and reduced bone mineral density in adult women. Can J Gastroenterol 2010, 24:103-107.
206. Pinto Sánchez M.I., Mohaidle A., Baistrocchi A., Matoso D., Vázquez H., González A., et al. Risk of fracture in celiac disease: Gender, dietary compliance, or both?. World J Gastroenterol 2011, 17:3035-3042.
207. Jafri M.R., Nordstrom C.W., Murray J.A., Van Dyke C.T., Dierkhising R.A., Zinsmeister A.R., et al. Long-term fracture risk in patients with celiac disease: a population-based study in Olmsted County, Minnesota. Dig Dis Sci 2008, 53:964-971.
208. Olmos M., Antelo M., Vazquez H., Smecuol E., Mauriño E., Bai J.C. Systematic review and meta-analysis of observational studies on the prevalence of fractures in celiac disease. Dig Liver Dis 2008, 40:46-53.
209. Drummond F.J., Annis P., O'Sullivan K., Wynne F., Daly M., Shanahan F., et al. Screening for asymptomatic celiac disease among patients referred for bone densitometry measurement. Bone 2003, 33:970-974.
210. González D., Sugai E., Gomez J.C., Oliveri M.B., Gomez Acotto C., Vega E., et al. Is it necessary to screen for celiac disease in postmenopausal osteoporotic women?. Calcif Tissue Int 2002, 71:141-144.
211. Laadhar L., Masmoudi S., Bahlous A., Zitouni M., Sahli H., Kallel-Sellami M. Is screening for celiac disease in osteoporotic post-menopausal women necessary?. Joint Bone Spine 2007, 74:510-511.
212. Legroux-Gérot I., Leloire O., Blanckaert F., Tonnel F., Grardel B., Ducrocq J.L., et al. Screening for celiac disease in patients with osteoporosis. Joint Bone Spine 2009, 76:162-165.
213. Katz S., Weinerman S. Osteoporosis and gastrointestinal disease. Gastroenterol Hepatology 2010, 6:506-517.
214. Taranta A., Fortunati D., Longo M., Rucci N., Iacomino E., Aliberti F., et al. Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. J Bone Miner Res 2004, 19:1112-1121.
215. Ciacci C., Cirillo M., Mellone M., Basile F., Mazzacca G., De Santo N. Hypocalciuria in overt and subclinical celiac disease. Am J Gastroenterol 1995, 90:1480-1484.
216. Moreno M.L., Crusius J.B.A., Cherñavsky A. The IL-1 gene family and bone involvement in celiac disease. Immunogen 2005, 57:618-620.
217. Riches P.L., McRorie E., Fraser W.D., Determann C., Van't Hof R., Ralston S.H. Osteoporosis Associated with Neutralizing Autoantibodies against Osteoprotegerin. N Engl J Med 2009, 361:1459-1465.
218. Mora S., Barera G., Ricotti A., Weber G., Bianchi C., Chiumelo G. Reversal of low bone density with a gluten-free diet in children and adolescents with celiac disease. Am J Clin Nutr 1998, 67:477-481.
219. Mora S., Barera G., Beccio S., Proverbio M., Weber G., Bianchi C., et al. Bone density and bone metabolism are normal after long-term gluten-free diet in Young celiac patients. Am J Gastroenterol 1999, 94:398-403.
220. Cellier C., Flobert C., Cormier C., Roux C., Schmitz J. Severe osteopenia in symptom-free adults with a childhood diagnosis of celiac disease. Lancet 2000, 355:806.
221. Matysiak-Budnik T., Malamut G., Patey-Mariaud de Serre N., Grosdidier E., Seguier S., Brousse N., et al. Long-term follow-up of 61 coeliac patient diagnosed in childhood: evolution toward latency is possible on a normal diet. Gut 2007, 56:1376-1386.
222. Kemppainen T., Kroger H., Janatuinen E., Arnala I., Lamberg-Allardt C., Karkkainen M., et al. Bone recovery after a gluten-free diet: a 5-year follow-up study. Bone 1999, 25:355-360.
223. Ciacci C., Maurelli L., Klain M., Savino G., Salavatore M., Mazzaca G., et al. Effects of dietary treatment on bone mineral density in adults with celiac disease: factors predicting response. Am J Gastroenterol 1997, 92:992-996.
224. Duerksen D.R., Leslie W.D. Longitudinal evaluation of bone mineral density and body composition in patients with positive celiac serology. J Clin Densitom 2011, 14:478-483.
225. Valdimarsson T., Toss G., Löfman O., Strõm M. Three years' follow-up of bone density in adult coeliac disease: significance of secondary hyperparathyroidism. Scand J Gastroenterol 2000, 35:274-280.
226. Mautalen C., Gonzalez D., Mazure R., Vazquez H., Lorenzetti M., Maurino E., et al. Effect of treatment on bone mass, mineral metabolism and body composition in untreated celiac disease patients. Am J Gastroenterol 1997, 92:313-318.
227. Pazianas M., Butcher G.P., Subhani J.M., Finch P.J., Ang L., Collins C., et al. Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake. Osteoporos Int 2005, 16:56-63.
228. Pinkerton J.V., Alan C., Dalkin A.C., Crowe S.E., Wilson B.B., Stelow E.B. Treatment of postmenopausal osteoporosis in a patient with celiac disease. Nat Rev Endocrinol 2010, 6:167-171.
229. Bjarnason I., Macpherson A., Mackintosh C., Buxton-Thomas M., Forgacs I., Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997, 40:228-233.
230. Pollak R.D., Karmeli F., Eliakim R., Ackerman Z., Kevin T., Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998, 93:1483-1490.
231. Jahnsen J., Falch J.A., Mowinckel P., Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 2004, 39:145-153.
232. Ardizzone S., Bollani S., Bettica P., BevilacquaM, MolteniP, Porro B. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000, 247:63-70.
233. Vestergaard P., Mosekilde L. Fracture risk in patients with celiac disease. Crohn's disease, and Ulcerative Colitis: a Nationwide Follow-up Study of 16,416 Patients in Denmark. Am J Epidemiol 2002, 156:1-10.
234. Bernstein C.N., Blanchard J.F., Leslie W., Wajda A., Yu N. The Incidence of Fracture among Patients with Inflammatory Bowel Disease. A Population-Based Cohort Study. Ann Intern Med 2000, 133:795-799.
235. Loftus E.V., Crowson C.S., Sandborn W.J., Ttremaine W.J., O'fallon W.M., Melton I.J. Long-Term Fracture Risk in Patients with Crohn's Disease: A Population-Based Study in Olmsted County, Minnesota. Gastroenterology 2002, 123:468-475.
236. Van Staa T.P., Cooper C., Brusse L.S., Brusse L.S., Leufkens H., Javaid M.K., et al. Inflammatory Bowel Disease and the Risk of Fracture. Gastroenterology 2003, 125:1591-1597.
237. Card T., West J., Hubbard R., Logan R.F. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004, 53:251-255.
238. Kornbluth A., Hayes M., Feldman S., Hunt M., Fried- BoxtE, Lichtiger S. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol 2006, 101:1546-1550.
239. Lewis N.R., Scott B.B. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. BSG Guidelines in Gastroenterology June 2007, 14:1-16.
240. Goodhand J.R., Kamperidis N., Nguyen H., Wahed M.M., Rampton D.S. Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Aliment Pharmacol Ther 2011, 33:551-558.
241. Kanis J.A., Hans D., Cooper C., Baim S., Bilezikian J.P., Binkley N., et al. Task Force of the FRAX Initiative. Interpretation and use of frax in clinical practice. Osteoporos Int 2011, 22:2395-2411.
242. Reffitt D.M., Meenan J., Sanderson J.D., Jugdaohsingh R., Powell J.J., Thompson R.P. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003, 15:1267-1273.
243. Bernstein C.N., Leslie W.D., Leboff M.S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841.
244. Franchimont N., Putzeys V., Collette J., Vermeire S., Rutgeerts P., De Vos M., et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004, 20:607-614.
245. Abreu M.T., Geller J.L., Vasiliauskas E.A., Kam L., Vora P., Martyak L., et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006, 40:55-63.
246. Ryan B.M., Russel M.G., Schurgers L., Wichers M., Sijbrandij J., Stockbrugger R.W., et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 2004, 20:851-857.
247. Ballesteros-Pomar M.D., Vidal A., CallejaA, López J.J., Urioste A., Cano I. Impacto de la nutrición en la evolución de la enfermedad inflamatoria intestinal. Nutr Hosp 2010, 25:181-192.
248. Haderslev K.V., Tjellesen L., Sorensen H.A., Stalin M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000, 119:639-646.
249. Henderson S., Hoffman N., Prince R. A double-blind placebo controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:119-123.
250. Tsujikawa T., Andoh A., Inatomi O., Bamba S., Nakahara T., Sasaki M. Alendronate Improves Low Bone Mineral Density Induced by Steroid Therapy in Crohn's Disease. Inter Med 2009, 48:933-937.
251. Bartram S.A., Peaston R.T., Rawlings D.J., Francis R.M., Thompson N.P. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003, 18:1121-1127.
252. Nelson H.D., Haney E.M., Bougatsos C., Chou R. Screening for Osteoporosis: An Update for the U.S Preventive Services Task Force. Ann Intern Med 2010, 153:99-111.
253. Soyka L.A., Grinspoon S., Levitsky L.L., Herzog D.B., Klibanski A. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 1999, 84:4489-4496.
254. Grinspoon S., Thomas E., Pitts S., Gross E., Micley D., Miller K., et al. Prevalence and predictive factors regional for osteopenia in women with anorexia nervosa. Ann Intern Med 2000, 133:790-794.
255. Nancy A., Rigotti M.D., Robert M., Neer M.D., Steven J., Skates P., et al. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 1991, 265:33-38.
256. Lucas A.R., Melton L.J., Crowson C.S., O'Fallon W.M. Long-term fracture risk among women with anorexia nervosa: A population-based cohort study. Mayo Clin Proc 1999, 74:972-977.
257. Herzog W., Minne H., Deter C., Leiding G., Schellberg D., Wuster C. Outcome of bone mineral density in anorexia nervosa patients 11,7 years after first admission. J Bone Miner Res 1993, 8:597-605.
258. Jacobson-Dickman E., Misra M. Skeletal Abnormalities in Anorexia Nervosa IBMS BoneKEy 2010, 7:63-83.
259. Mehler P.S., Cleary B.S., Gaudiani J.L. Osteoporosis in anorexia nervosa. Eat Disord 2011, 19:194-202.
260. Misra M., Klibanski A. Bone metabolism in adolescents with anorexia nervosa. J Endocrinol Invest 2011, 34:324-332.
261. Misra M., Klibanski A. Bone health in anorexia nervosa. Curr Opin Endocrinol Diabetes Obes 2011, 18:376-382.
262. Bachrach L.K., Guido D., Katzman D., Litt I.F., Marcus R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics 1990, 86:440-447.
263. Turner J.M., Bulsara M.K., McDermott B.M., Byrne G.C., Prince R.L., Forbes D.A. Predictors of low bone density in young adolescent females with anorexia nervosa and other dieting disorders. Int J Eat Disord 2001, 30:245-251.
264. Fernández Soto M.L., González Jiménez A., Varsavsky M. Bone metabolism and fracture risk in anorexia nervosa. Med Clin (Barc) 2010, 135:274-279.
265. Klibanski B.M., Biller D.A., Schoenfeld D.B., Herzog D.B., Saxe V.C. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 1995, 80:898-904.
266. Karlsson M.K., Weijall S.J., Duan Y., Seemen E. Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women received from anorexia nervosa. J Clin Endocrinol Metab 2000, 85:3177-3182.
267. Golden N.H., Iglesias E.A., Jacobson M.S., Carey D., Meyer W., Hertz S., et al. Alendronate for the treatment of osteopenia in anorexia nervosa: A randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005, 90:3179-3185.
268. Miller K.K., Grieco K.A., Mulder J., Grinspoon S., Mickley D., Yehezkel R., et al. Effects of risedronate on bone density in anorexia nervosa. J Clin Endocrinol Metab 2004, 89:3903-3906.
269. Foldes J., Rimon B., Muggia-Sullam M., Gimmon Z., Leichter I., Steinberg R., et al. Progressive bone loss during long-term home parenteral nutrition. JPEN 1990, 14:139-142.
270. Von Wowern N., Klausen B., Hylander E. Bone loss and oral state in patients on home parenteral nutrition. JPEN 1996, 20:105-109.
271. Van Gossum A., Vahedi K., Malik A., Satun M., Pertkiewitcz M., Schaffer J., et al. Clinical, social, and rehabilitation status of long-term home parenteral nutrition patients: results of a European multicentre survey. Clin Nutr 2001, 20:205-210.
272. Cohen Solal M., Baudoin C., Joly F., Vahedi K., D'Aoust L., de Vernejoul M.C., et al. Osteoporosis on long-term home parenteral nutrition: a longitudinal study. J Bone Miner Res 2003, 18:1989-1994.
273. Pironi L., Morselli A.M., Pertkiewitcz M., Przedlacki J., Tjellesen L., Staun M., et al. Prevalence of bone disease in patients on home parenteral nutrition. Clin Nutr 2002, 21:289-296.
274. Haderslev K.V., Tjellesen L., Haderslev P.H., Staun M. Assessment of the longitudinal changes in patients receving home parenteral nutrition. JPEN 2004, 28:289-294.
275. Raman M., Gramlich L., Whittaker S., Allard J.P. Canadian home parenteral nutrition registry: preliminary data on patient population. Can J Gastroenterol 2007, 21:643-648.
276. Martínez C., Virgili N., Cuerda C., Chicharro L., Gómez P., Moreno J.M., et al. Estudio transversal sobre la prevalencia de enfermedad metabólica ósea y nutrición parenteral domiciliaria en España. Nutr Hosp 2010, 25:920-924.
277. Tjellesen L., Staun M., Rannem T., Nielsen K., Jarnum S. Body composition in patients on home parenteral nutrition. Scan J Clin Lab Invest 1996, 56:295-303.
278. Pironi L., Tjellesen L., De Francesco A., Pertkiewitcz M., Morselli Labate A.M., Staun M., et al. Bone mineral density in patients on home parenteral nutrition: a follow-up study. Clin Nutr 2004, 23:1288-1302.
279. Matarese L.E., Steiger E., Seidner D.L., Richmond B. Body composition changes in patients receiving home parenteral nutrition. JPEN 2002, 26:366-371.
280. Pironi L., Maghetti A., Zolezzi C., Ruggeri E., Incasa E., Gnudi S., et al. Bone turnover in patients on home parenteral nutrition: a longitudinal observation by biochemical markers. Clin Nutr 1996, 15:157-163.
281. Haderslev K.V., Tjellesen L., Sorensen H.A. Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition. Am J Clin Nutr 2002, 76:482-488.
282. Raman M., Aghdassi E., Baun M., Yeung M., Fairholm L., Saqui O., et al. Metabolic bone disease on patients receiving home parenteral nutrition: a Canadian study and review. JPEN 2006, 30:492-496.